comparemela.com

Ximing Ding News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Engimmune Therapeutics raises CHF 15 5 million in seed financing to develop novel T-cell receptor therapeutics | DNA RNA and Cells

Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics

Stephan emmerthDominik escherPureos bioventuresRodrigo vazquez lombardiNovo nordiskPartner at novo holdingsNovo groupNovo nordisk foundationNovo holdings to engimmuneNovo holdingsEngimmune therapeuticsSwitzerlandi mayProf sai reddyChief scientificEnovo seedsBoard directors

Engimmune Therapeutics raises CHF 15 5 million in seed financing to develop novel T-cell receptor therapeutics

/PRNewswire/ Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the.

Stephan emmerthDominik escherPureos bioventuresRodrigo vazquez lombardiNovo nordiskPartner at novo holdingsNovo groupNovo nordisk foundationNovo holdings to engimmuneNovo holdingsProf sai reddyChief scientificEnovo seedsBoard directorsXiming dingChief executive officer

Engimmune Therapeutics Raises CHF 15 5M in Seed Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Dominik escherPureos bioventuresRodrigo vazquez lombardiNovo holdingsEngimmune therapeuticsProf sai reddyChief scientificBoard directorsXiming ding

vimarsana © 2020. All Rights Reserved.